AMENDMENTS TO THE CLAIMS

Docket No.: 09857/0204372-US0

This listing of claims will replace all prior version, and listings, of claims in the application:

Claim 1 (Currently Amended): A hERG channel-expressing cell population comprising cells capable of expressing a channel of which the hERG current as determined by patch clamping with a fully automated high throughput patch clamp system is 0.6 nA or more, wherein the <u>proportion ratio</u> of said cells is 40% or more relative to the total number of hERG gene-transferred cells within said population.

Claim 2 (Original): The cell population according to claim 1, wherein the hERG gene has been transferred with a virus vector.

Claim 3 (Original): The cell population according to claim 2, wherein the virus vector is a retrovirus vector or a lentivirus vector.

Claim 4 (Currently Amended): The cell population according to any one of claims 1 to 3 claim 1, wherein the average value of the hERG current in the total cell population cells is 0.3 nA or more.

Claim 5 (Original): A cell capable of expressing a hERG channel of which the hERG current as determined by patch clamping with a fully automated high throughput patch clamp system is 1.0 nA or more.

Claim 6 (Original): The cell according to claim 5, wherein the hERG gene has been transferred with a virus vector.

Claim 7 (Original): The cell according to claim 6, wherein the virus vector is a retrovirus vector or a lentivirus vector.

Claim 8 (Currently Amended): A method of preparing the cell population according to any one of claims 1 to 4 or the cell according to any one of claims 5 to 7 claim 1, the method comprising which comprises expressing hERG channels using via a virus vector.

Docket No.: 09857/0204372-US0

Claim 9 (Original): The method according to claim 8, wherein the virus vector is a retrovirus vector or a lentivirus vector.

Claim 10 (Canceled): The method according to claim 8, wherein the virus vector is a retrovirus vector.

Claim 11 (Currently Amended): The method according to <u>claim 8 any one of claims 8 to 10</u>, <u>the method further comprising the which comprises a step of concentrating the virus vector by ultracentrifugation.</u>

Claim 12 (Currently Amended): A method of measuring hERG current inhibitory activity, <u>the</u> <u>method comprisingwhich comprises</u> using the cell population according to <u>any one of claims 1 to 4</u> or the cell according to any one of claims 5 to 7claim 1.

Claim 13 (Currently Amended): The method according to claim 12, the method further comprising which comprises using a fully automated high throughput patch clamp system.

Claim 14 (Currently Amended): A method of measuring hERG current inhibitory activity, the method comprising which comprises using a cell population or a cell prepared by the method according to any one of claims 8 2, orto 11claim 8.

Claim 15 (Currently Amended): The method according to claim 14, the method further comprising which comprises using a fully automated high throughput patch clamp system.

Application No. National Phase of PCT/JP2004/017441 5 Amendment dated May 16, 2006 First Preliminary Amendment

Claim 16 (Currently Amended): A method of screening a compound for compounds, or a saltsalts thereof for its hERG current altering effect, that alter or not alter hERG currents, the method comprising which comprises using the cell population according to any one of claims 1 to 4 or the cell according to any one of claims 5 to 7 claim 1.

Docket No.: 09857/0204372-US0

Claim 17 (Currently Amended): The method according to claim 16, the method further comprising which comprises using a fully automated high throughput patch clamp system.

Claim 18 (Currently Amended): A method of screening a compound for compounds, or a saltsalts thereof for its hERG current altering effect, that alter or not alter hERG currents, the method comprising which comprises using a cell population or a cell prepared by the method according to any one of claims 8 9, orto 11 claim 8.

Claim 19 (Currently Amended): The method according to claim 18, the method further comprising which comprises using a fully automated high throughput patch clamp system.

Claim 20 (New): A method of measuring hERG current inhibitory activity, the method comprising using the cell population according to claim 5.

Claim 21 (New): A method of screening a compound or a salt thereof for its hERG current altering effect, the method comprising using the cell population according to claim 5.

 $\{W: \label{eq:weighted} \ \{W: \label{eq:we$